by Molecular biology research is central to understanding genetic disorders, from identifying disease-associated variants to studying gene expression, mutations, and molecular pathways. These workflows depend on high-quality reagents for DNA and RNA extraction, PCR, sequencing, cloning, amplification, and genomic analysis.
For researchers, choosing a reagent supplier is not simply about product availability. Consistency, application support, product breadth, quality control, supply reliability, and experience across molecular biology workflows can all influence laboratory performance.
This article ranks leading suppliers using 2025 publicly reported financial data as a scale indicator, while also considering their relevance to molecular biology research.
Ranking methodology: The ranking is primarily based on the latest publicly reported 2025 revenue of the companies’ relevant life-science businesses. These figures should not be interpreted as molecular biology reagent market share or as a scientific quality score.
Top Companies for Molecular Biology Reagents
| Rank | Company | 2025 Relevant Revenue | Key Strength |
|---|---|---|---|
| 1 | Merck / Sigma-Aldrich | €8.98B (~$10.15B) | Broad life-science and laboratory portfolio |
| 2 | Thermo Fisher Scientific | $8.78B external Life Sciences Solutions revenue | Genetic sciences, biosciences and molecular biology |
| 3 | QIAGEN | $2.09B | Sample preparation, PCR and genomics |
| 4 | Bio-Rad Laboratories | $1.02B Life Science revenue | PCR, digital PCR and molecular analysis |
| Specialist | New England Biolabs (NEB) | Not publicly disclosed | Molecular biology enzymes and reagents |
*Approximate USD conversion for Merck uses the ECB’s 2025 average USD/EUR rate of 1.13. *
1. Merck / Sigma-Aldrich
Merck ranks first in this scale-based comparison because its Life Science business generated €8.98 billion in 2025, equivalent to approximately $10.15 billion using the ECB’s 2025 average exchange rate.
Merck’s Life Science business includes Science & Lab Solutions, Process Solutions, and Life Science Services. Science & Lab Solutions alone generated €4.536 billion in 2025.
For molecular biology laboratories, the Sigma-Aldrich portfolio is relevant across areas such as:
- DNA and RNA research
- PCR
- Enzymes
- Nucleotides
- Buffers and chemicals
- Gene expression research
- Cell and molecular biology
- Genomics workflows
Why researchers consider it: The major advantage is portfolio breadth, allowing laboratories to source many research chemicals and molecular biology products from one established supplier.
2. Thermo Fisher Scientific
Thermo Fisher Scientific generated $10.374 billion in 2025 Life Sciences Solutions segment revenue, including intersegment revenue. On an external-customer basis, the segment generated approximately $8.781 billion.
The company reported $44.56 billion in total 2025 revenue, up 4% from 2024.
Its Life Sciences Solutions portfolio includes:
- Biosciences
- Genetic sciences
- Bioproduction
- Molecular biology reagents
- PCR products
- Nucleic-acid technologies
- Genomic analysis products
The Genetic Sciences business generated $2.87 billion in 2025, while Biosciences generated $4.169 billion.
Why researchers consider it: Thermo Fisher combines reagents with instruments, consumables, sequencing and genetic-analysis technologies, making it particularly relevant for laboratories running integrated molecular biology workflows.
3. QIAGEN
QIAGEN reported $2.09 billion in 2025 net sales, representing 6% growth from $1.978 billion in 2024. Importantly, consumables and related revenues accounted for $1.876 billion, or approximately 90% of total sales.
Its 2025 product-group performance included:
- Sample technologies: $661.3 million
- Diagnostic solutions: $803.1 million
- PCR/nucleic-acid amplification: $309.0 million
- Genomics/NGS: $241.8 million
QIAGEN also reported that its addressable Life Sciences and molecular diagnostics market was approximately $12 billion annually, with expected annual growth of about 4–6% through 2028.
Why researchers consider it: QIAGEN has particular strength in sample preparation, nucleic-acid purification, PCR and genomic workflows.
4. Bio-Rad Laboratories
Bio-Rad generated $2.583 billion in total revenue in 2025, with approximately 40% coming from its Life Science segment. The company’s Life Science revenue was approximately $1.021 billion, down 0.7% year over year on a currency-neutral basis.
Bio-Rad’s molecular biology portfolio includes applications such as:
- PCR
- Digital PCR
- Gene expression
- Electrophoresis
- Nucleic-acid analysis
- Molecular research reagents
- Research instruments and consumables
Why researchers consider it: Bio-Rad is particularly recognized for integrating reagents with PCR and molecular-analysis platforms.
Specialist: New England Biolabs
New England Biolabs, commonly known as NEB, is different from the publicly traded companies above because it does not provide comparable public financial disclosures.
Therefore, it would be misleading to assign NEB a revenue-based rank alongside the other companies.
Instead, NEB should be viewed as a specialist molecular biology supplier, particularly known for enzymes and reagents used in:
- DNA manipulation
- PCR
- Cloning
- Restriction digestion
- DNA assembly
- RNA research
- Library preparation
- Sequencing workflows
For researchers focused specifically on molecular biology enzymes, NEB can be an important supplier even though its financial scale cannot be directly compared using publicly reported revenue.
What Do the Numbers Tell Us?
The financial data show the scale of the companies’ relevant businesses, but they do not prove that one company’s reagent is scientifically superior to another’s.
For example, Thermo Fisher’s 2025 Life Sciences Solutions business generated $8.781 billion in external revenue, while QIAGEN generated $2.09 billion in total net sales. QIAGEN’s business, however, is much more concentrated in consumables, with consumables and related revenues accounting for 90% of its 2025 sales.
Similarly, Bio-Rad’s Life Science business generated approximately $1.02 billion, but the company also operates a substantial Clinical Diagnostics business, which accounted for approximately 60% of its total 2025 revenue.
This is why revenue should be treated as a company-scale indicator rather than a reagent-quality ranking.
What Should Researchers Look for When Selecting Reagents?
1. Product validation
Check whether the reagent has been validated for the intended application and sample type.
2. Purity and quality control
Review specifications, certificates of analysis, storage requirements, and quality-control information.
3. Lot consistency
For long-term genetic studies, consistent performance between reagent lots can help reduce experimental variation.
4. Application compatibility
A reagent suitable for conventional PCR may not be the right choice for qPCR, sequencing, cloning, or next-generation sequencing workflows.
5. Technical support
Strong protocols, application notes, troubleshooting resources, and technical assistance can be valuable during method development.
6. Supply availability
Researchers should consider lead times, distribution networks, cold-chain requirements, and product availability when selecting a long-term supplier.
Why Reagent Selection Matters in Genetic Disorder Research
Genetic disorder research often involves several connected laboratory stages.
A typical workflow may include:
Biological sample → DNA/RNA extraction → PCR or amplification → sequencing/genotyping → molecular analysis
A problem at any stage can affect downstream results. Reliable reagents therefore play an important role in maintaining reproducible research workflows.
For studies involving rare variants or disease-associated mutations, researchers may also need highly consistent reagents when comparing samples across different experimental batches.
Ranking
Based on 2025 reported relevant-business revenue, the leading companies in this comparison are:
1. Merck / Sigma-Aldrich
€8.98B Life Science revenue (~$10.15B)
2. Thermo Fisher Scientific
$8.78B external Life Sciences Solutions revenue
3. QIAGEN
$2.09B total 2025 net sales
4. Bio-Rad Laboratories
$1.02B Life Science revenue
Specialist: New England Biolabs
Private company – comparable revenue not publicly disclosed
The ranking should be interpreted as a scale-based comparison, not a definitive ranking of reagent quality. For researchers, the best supplier ultimately depends on the specific genetic disorder research application, reagent requirements, validation data, budget, and laboratory workflow.
Expert View by Payal Rabde – highlighting the trends shaping the future of healthcare.
Frequently Asked Questions
Which company is the largest among these suppliers?
Using 2025 reported relevant-business revenue as the ranking metric, Merck’s Life Science business was the largest in this comparison, followed by Thermo Fisher Scientific’s external Life Sciences Solutions revenue.
Which company is strongest for PCR and molecular biology?
Thermo Fisher, QIAGEN, Bio-Rad, Merck/Sigma-Aldrich, and NEB all have important molecular biology offerings. The most suitable choice depends on the specific PCR, sequencing, cloning, or genomic application.
Why isn’t NEB given a numerical ranking?
NEB is privately held and does not provide comparable public revenue figures. Giving it an estimated financial rank would make the comparison less reliable.
About Us
Pharma Geek is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium
